JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Alnylam Pharmaceuticals Reports Second Quarter 2015 Financial Results and Highlights Recent Period Activities
August 6, 2015 4:00 PM EDTAdvanced Pipeline of Seven Investigational Clinical Programs and Presented Positive Clinical Results for Three: Patisiran for Familial Amyloidotic Polyneuropathy (FAP), ALN-AT3 for Hemophilia, and ALN-CC5 for Complement-Mediated Diseases
In Addition to Upcoming Presentation of ALN-PCSsc Clinical Results, Announces New Plan to Present Initial Clinical Data for ALN-AS1 Porphyria Program at Medical Meeting in September and Provides Update on Revusiran Phase 2 Open-Label Extension Study
Maintained Strong Balance Sheet with $1.40 Billion in Cash and Remains On Track to End 2015 with Greater than $1.2 Billion in Cash
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
